Phylicia Aaron

Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial

Rodney P. Rocconi, Elizabeth A. Grosen, Sharad Ghamande et al. · The Lancet Oncology · 2020 · 112 citations

Medicine, Immunology, Gynecology +6

The blood-brain barrier internalises<i>Cryptococcus neoformans</i>via the EphA2-tyrosine kinase receptor

Phylicia Aaron, Mantana Jamklang, John P. Uhrig et al. · Cellular Microbiology · 2017 · 69 citations · Full text

Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer

Rodney P. Rocconi, Bradley J. Monk, Adam Walter et al. · Gynecologic Oncology · 2021 · 35 citations

Radiation Oncology, Homologous Recombination Proficient, Cell Therapy +8

An Antivirulence Approach for Preventing Cryptococcus neoformans from Crossing the Blood-Brain Barrier via Novel Natural Product Inhibitors of a Fungal Metalloprotease

Phylicia Aaron, Kiem Vu, Angie Gelli · mBio · 2020 · 25 citations · Full text

Proof of principle study of sequential combination atezolizumab and Vigil in relapsed ovarian cancer

Rodney P. Rocconi, Erin Stevens, Justin Bottsford-Miller et al. · Cancer Gene Therapy · 2021 · 23 citations

Medicine, Cancer Management, Principle Study +7